Home›Companies›Biotech & Pharma›AEMS

Aems Corp.

AEMS develops drug formulations for biologic drug developers.

Updated Nov 9, 2026·Latest SEC filing Sep 18, 2026·Suggest an edit

About AEMS

AEMS is a private company based in Denver, Colorado. It has reported $820,000 raised in five offerings on Form D since August 2020. Its chief executive is William Compel.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Sep 9, 2026Sep 18, 2026$95,000of $1.0M target3$31,667EquityRule 506(b)Form D ↗
Mar 5, 2026Mar 9, 2026$100,000of $700K target4$25,000Equity, DebtRule 506(b)Form D ↗
May 9, 2025May 21, 2025$225,000of $500K target4$56,250Equity, DebtRule 506(b)Form D ↗
Oct 19, 2022Nov 14, 2022amended Oct 12, 2023$250,000fully sold4$62,500Equity, DebtRule 506(b)Form D/A ↗1 earlier filing
Jul 27, 2020Aug 5, 2020$150,000of $200K target2$75,000EquityRule 506(b)Form D ↗
Total, five offerings$820,000

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on AEMS's Form D filed Sep 18, 2026.

NT
Nick Traggis
Director
Also an executive officer and director at Ambrosia Biosciences.
WC
William Compel
CEO and director

Earlier filings also listed Nicholas Collella (director, last listed Oct 2023) and Nicholas Colella (director, last listed Aug 2020).

Sources

  1. SECAEMS Corp. Form D, filed Nov 14, 2022
  2. SECAEMS Corp. filing history